Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04410796 · ClinicalTrials.gov registry record · Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
A Phase 2 study of Metastatic Non Small Cell Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 571
- Enrollment target
- 18
- Study locations
NCT04410796 is a Phase 2 study of Metastatic Non Small Cell Lung Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 571 participants, above the 375-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (52% higher). The trial reports 18 study locations across 9 states.
The verdict
NCT04410796, a Phase 2 study of Metastatic Non Small Cell Lung Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 571 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to osimertinib could possibly add to the anticancer effects of the usual treatment and help stop cancer from growing or spreading.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Osimertinib
- DRUG Pemetrexed
Study Locations (18)
New York
- Memorial Sloan Kettering Commack (Limited protocol activities) - Commack
- Memorial Sloan Kettering Westchester (Limited protocol activities) - Harrison
- New York University - New York
- Columbia University (Data Collection Only) - New York
- Memorial Sloan Kettering Cancer Center (All protocol activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Hackensack Meridian Health - Hackensack
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
California
- UC Davis Cancer Center (Data Collection Only) - Sacramento
- University of California San Francisco - San Francisco
Florida
- Moffitt Cancer Center - Tampa
Maryland
- John Hopkins Medical Center - Baltimore
Massachusetts
- Massachusetts General Hospital (Data Collection Only) - Boston
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- MD ANDERSON CANCER CENTER (Data Collection Only) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04410796
The ClinicalTrials.gov registry entry for NCT04410796 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 571 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 375-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (52% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT04410796 reports 18 study locations spanning 9 distinct geographic areas - top geographies include New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT04410796 about?
NCT04410796 is a clinical study titled "Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers". This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lu...
What is the current status of trial NCT04410796?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 571 participants. The study started on 2020-05-28. Estimated completion is 2026-05.
What conditions does trial NCT04410796 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT04410796?
The interventions under investigation include: Carboplatin (DRUG), Osimertinib (DRUG), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT04410796?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04410796 being conducted?
This trial has 18 study locations across California, Florida, Maryland, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RECRUITING · Phase 2
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RECRUITING · Phase 2
-
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
-
Plasma-Adapted First-Line Pembro In NSCLC
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.